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OBJECTIVES We performed a study to assess the efficacy of fenoldopam mesylate (a specific agonist of the
dopamine-1 receptor) as compared with N-acetylcysteine (NAC) in preventing contrast
agent-associated nephrotoxicity (CAN).
BACKGROUND Prophylactic administration of NAC, along with hydration, prevents CAN in patients with
chronic renal insufficiency who are undergoing contrast media administration. Preliminary
data support the hypothesis that fenoldopam might be as effective as NAC.
METHODS One hundred ninety-two consecutive patients with chronic renal insufficiency, referred to our
institution for coronary and/or peripheral procedures, were assigned randomly to receive
0.45% saline intravenously and NAC (1,200 mg orally twice daily; NAC group; n  97) or
fenoldopam (0.10 g/kg/min; fenoldopam group; n  95) before and after a nonionic,
iso-osmolality contrast dye administration.
RESULTS Baseline creatinine levels were similar in the two groups: NAC group  1.72 mg/dl
(interquartile range, 1.55 to 1.90 mg/dl) and fenoldopam group  1.75 mg/dl (interquartile
range, 1.62 to 2.01 mg/dl) (p  0.17). An increase of at least 0.5 mg/dl of the creatinine
concentration 48 h after the procedure occurred in 4 of 97 patients (4.1%) in the NAC group
and in 13 of 95 patients (13.7%) in the fenoldopam group (p  0.019; odds ratio 0.27; 95%
confidence interval 0.08 to 0.85). The amount of contrast media administration was similar
in the two groups (NAC group  160  82 ml; fenoldopam group  168  104 ml; p 
0.54).
CONCLUSIONS N-acetylcysteine seems to be more effective than fenoldopam in preventing CAN. (J Am
Coll Cardiol 2004;44:762–5) © 2004 by the American College of Cardiology FoundationM
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Eadiocontrast media can lead to a reversible form of acute renal
ailure that, especially in high-risk patients, may require tran-
ient dialysis and may impair in-hospital and long-term out-
omes (1–3). The two major mechanisms of contrast-
ssociated nephrotoxicity (CAN) are renal vasoconstriction (4)
nd direct toxic effects of the contrast agents (5,6). Recom-
endations to prevent CAN are: 1) periprocedural hydration
7), 2) the use of a low- or iso-osmolality contrast (8–11), and
) limiting the amount of contrast agent (12). Recently, two
dditional strategies associated with to hydration aroused
onsiderable interest: N-acetylcysteine (NAC) and fenoldo-
am mesylate; the former, a potent antioxidant compound,
ay prevent the direct oxidative tissue damage by scavenging
eactive oxygen species (13), whereas the latter, a specific
opamine-1 receptor agonist that causes peripheral vasodilata-
ion via stimulation of postsynaptic dopamine-1 receptors (14),
ay prevent renal vasoconstriction (15–18).
We performed a prospective, randomized trial comparing
he safety and prophylactic effectiveness of NAC plus
ydration versus fenoldopam mesylate plus hydration in
atients with chronic renal insufficiency undergoing coro-
ary or peripheral artery procedures.
From the *Laboratory of Interventional Cardiology and Department of Cardiology,
linica Mediterranea, Naples, Italy; and †Laboratory of Interventional Cardiology,
Vita e Salute” University School of Medicine, Milan, Italy.
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atient population. This is a prospective, randomized study
onducted in our institutions from March to December 2003.
he local ethics committee (“Vita e Salute” University School
f Medicine, Milan, Italy) approved the study protocol. All
atients gave written informed consent. Consecutive patients
cheduled for elective coronary and/or peripheral angiography
nd/or angioplasty were eligible for the study if they had
hronic impairment of renal function (serum creatinine con-
entration 1.5 mg/dl and/or creatinine clearance 60 ml/
in) and stable serum creatinine concentrations. Patients were
andomly assigned to receive intravenous saline plus NAC
NAC group) or fenoldopam mesylate (fenoldopam group)
efore and after administration of iodixanol (Visipaque, 320
g iodine/ml, Amersham Health, Amersham, United King-
om) a non-ionic, iso-osmolality contrast agent. Saline
0.45%) was given intravenously at a rate of 1 ml/kg of body
eight/h (0.5 ml/kg for patients with left ventricular ejection
raction [LVEF] 40%) for 12 h before and 12 h after
dministration of the contrast agent (7). N-acetylcysteine
Fluimucil, Zambon Group Spa, Milan, Italy) was given orally
t a dose of 1,200 mg twice daily in the NAC group on the day
efore and on the day of administration of the contrast agent
or a total of two days (19). Fenoldopam mesylate (Corlopam,
lan Pharma Italia, Rome, Italy) infusion was started at least
h before the procedure at 0.10 g/kg/min, maintained
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August 18, 2004:762–5 Contrast Media and Acute Renal Failureuring the procedure, and continued for 12 h after the
rocedure. The dosage was downtitrated or discontinued in
ases of hypotension or tachycardia (20). Severe hypotension
as defined as a systolic blood pressure90 mm Hg. None of
he patients received theophylline, dopamine, mannitol, or
urosemide during the study. Serum creatinine, blood urea
itrogen, sodium, and potassium were measured immediately
efore and 48 h after administration of the contrast agent;
dditional measurements were performed in all cases of signif-
cant impairment of renal function. Creatinine clearance was
alculated by applying the Cockcroft-Gault formula (21).
tudy end point. Contrast agent-associated nephrotoxicity
as defined as an increase in the serum creatinine concen-
ration 0.5 mg/dl of the baseline value 48 h or need for
ialysis after administration of the contrast media (8).
cute renal failure requiring dialysis was defined as a
ecrease in renal function necessitating acute hemodialysis,
ltrafiltration, or peritoneal dialysis in the first five days
ostintervention.
Table 1. Clinical Characteristics of Patients Tr
With Fenoldopam
NAC
(n 
Age (yrs) 68
Male 84 (8
Weight (kg) 75
Height (m) 1.68
Body mass index (kg/m2) 26
Blood pressure (mm Hg)
Systolic 136
Diastolic 77
Mean 97
Left ventricular ejection fraction (%) 52
Systemic hypertension 74 (7
Diabetes mellitus 49 (5
Peripheral chronic artery disease 31 (3
Drugs
ACE inhibitor 52 (5
Calcium channel blocker 36 (3
Angiotensin II receptor inhibitor 15 (1
Diuretic 44 (4
Beta-blockers 38 (3
Performed procedure
Coronary angiography 43 (4
PCI 20 (2
Coronary angiography and ad hoc
PCI
24 (2
Peripheral angiography 4 (4
Peripheral angioplasty 6 (6
Total amount of hydration (ml) 1,798
Volume of contrast media (ml) 160
140 ml 54 (5
Abbreviations and Acronyms
CAN  contrast agent-associated nephrotoxicity
LVEF  left ventricular ejection fraction
NAC  N-acetylcysteineACE  angiotensin-converting enzyme; NAC  N-acetylcysteinetatistical analysis. A total sample size of 180 subjects
andomized with a 1:1 allocation ratio was calculated to
chieve a power (1 ) of 90% to detect a difference of 10%
etween the null hypothesis that both group proportions are
% and the alternative hypothesis that the proportion in the
AC group is 5% (19) and in the fenoldopam group is 15%
17,20) using a two-sided chi-square test with a significance
evel of 0.05. Continuous variables are given as mean  1
D or median and interquartile ranges. An unpaired Stu-
ent t test was performed to determine differences between
ean values for continuous variables when appropriate.
ategorical variables were analyzed by using the chi-square
est. Creatinine concentration was not normally distributed;
herefore, the nonparametric Wilcoxon rank-sum test and
ann-Whitney U test were used to assess differences.
robability values 0.05 were considered significant. Data
ere analyzed with SPSS 10.0 (SPSS Inc., Chicago, Illi-
ois) for Windows.
ESULTS
linical characteristics. The clinical and biochemical
haracteristics of the 192 enrolled patients are shown in
ables 1 and 2. Three patients experienced side effects in
he fenoldopam group that necessitated premature drug
nfusion discontinuation: two patients had severe hypoten-
With N-Acetylcysteine and
p Fenoldopam Group
(n  95) p Value
69  8 0.30
79 (83%) 0.51
74  12 0.80
1.68  0.6 0.98
26  3 0.94
137  20 0.80
75  11 0.22
96  12 0.55
51  11 0.61
72 (76%) 0.94
) 49 (52.1%) 0.83
36 (38%) 0.33
61 (65%) 0.12
47 (50%) 0.14
12 (13%) 0.51
36 (38%) 0.27
42 (44%) 0.49
45 (47%) 0.67
13 (13.5%) 0.10
24 (25%) 0.93
9 (9.5%) 0.14
4 (3.5%) 0.54
8 1,805  283 0.99
168  104 0.54
48 (50.5%) 0.52eated
Grou
97)
 9
7%)
 15
 0.7
 5
 19
 10
 12
 12
7%)
0.5%
2%)
4%)
7%)
6%)
6%)
9%)
4%)
1%)
5%)
%)
%)
 34
 82
5%); PCI  percutaneous coronary intervention.
s
a
v
h
f
H
d
H
m
g
C
a
i
f
c
a
p
f
g
f
t
g
r
f
g
f
i
(
d
f
f
s
H
L
m
e
s
h
t
2
D
C
t
d
c
u
w
f
N
N
w
s
N
d
2
i
A
p
t
C
F
c
N
p
e
764 Briguori et al. JACC Vol. 44, No. 4, 2004
Contrast Media and Acute Renal Failure August 18, 2004:762–5ion (one patient 2 h and the other 4 h after the procedure),
nd one patient had an allergic reaction (skin rash and
omiting) before the procedure. We found a trend to an
igher absolute decrease in systolic blood pressure in the
enoldopam group than in the NAC group (17  20 mm
g vs. 11  25 mm Hg; p  0.068). In contrast, the
ecrease in diastolic (9  11 mm Hg vs. 9  14 mm
g; p  1.00) and mean (11  12 mm Hg vs. 8  15
m Hg; p  0.30) blood pressure was similar in the two
roups.
ontrast agent-associated nephrotoxicity. Contrast
gent-associated nephrotoxicity occurred in 4 of 97 patients
n the NAC group (4.1%) and in 13 of 95 patients in the
enoldopam group (13.7%; p  0.019; odds ratio 0.27; 95%
onfidence interval 0.08 to 0.85) (Fig. 1). Contrast agent-
ssociated nephrotoxicity occurred in 5 of 11 (45.5%)
atients with serum creatinine level 2.5 mg/dl in the
enoldopam group versus 1 of 9 (11%) patients in the NAC
roup (p  0.095). In the 98 diabetic patients, renal
unction deterioration occurred in 4 of 49 (8.2%) patients in
he fenoldopam group and in 3 of 49 (6.1%) in the NAC
roup (p  0.72). In the 23 patients with LVEF 40%,
enal function deterioration occurred in 4 of 13 (13.3%) in
enoldopam group and none of the 10 patients in the NAC
roup (p  0.23). In patients with LVEF 40%, renal
unction deterioration occurred in 9 of 72 (12.5%) patients
Table 2. Biochemical Characteristics of Patien
Fenoldopam
NA
(
Serum creatinine, median (IQR), mg/dl
Baseline 1.72
After 48 h 1.60
Serum creatinine (2.5 mg/dl) 9
Creatinine clearance (ml/min)
Serum urea nitrogen (mg/dl)
Baseline
After 48 h
Serum sodium (mEq/l)
Baseline 1
After 48 h 1
Serum potassium (mEq/l)
Baseline 4
After 48 h 4
IQR  interquartile range; NAC  N-acetylcysteine.
igure 1. Schematic representation of the distribution of the occurrence of
ontrast agent-associated nephrotoxicity in patients treated with the
-acetylcysteine (NAC group) and with fenoldopam mesylate (fenoldo-
am group). Filled areas  cases with event; open areas  cases without
uvent.n fenoldopam group and 4 of 87 (4.5%) in the NAC group
p  0.085). No cases of CAN were observed in the 16
iabetic patients with LVEF 40% (7 patients in the
enoldopam group and 9 in the NAC group). In the
enoldopam group, mean blood pressure lowering was
imilar in patients with and without CAN (11  11 mm
g vs. 11  10 mm Hg; p  0.95) and in patients with
VEF 40% and 40% (13  9 mm Hg vs. 10  12
m Hg; p  0.39).
Renal failure requiring dialysis occurred in one patient
nrolled in the fenoldopam group (1.1%): this patient
ubsequently experienced in-hospital death. Length of in-
ospital stay (from admission to discharge) was longer in
he fenoldopam group than NAC group (5.0  10 days vs.
.9  2.7 days; p  0.049).
ISCUSSION
ontrast agent-associated nephrotoxicity represents the
hird cause of in-hospital renal function deterioration after
ecreased renal perfusion and postoperative renal insuffi-
iency (22). An optimal strategy to prevent CAN remains
nknown. Recently, two additional strategies associated
ith hydration aroused considerable interest: NAC and
enoldopam mesylate.
AC and CAN. The quite low incidence of CAN in the
AC group (4.1%) observed in the present study confirms
hat we previously reported (19). A potent antioxidant that
cavenges a wide variety of oxygen-derived free-radicals,
AC may prevent CAN by avoiding direct oxidative tissue
amage and also by improving renal hemodynamics (23–
5). Tepel et al. (13) first reported that NAC plus hydration
s more effective than hydration alone in preventing CAN.
recent meta-analysis evaluating more than 800 high-risk
atients enrolled in randomized controlled trials supports
hat NAC plus hydration significantly reduces the risk of
AN in patients with chronic renal insufficiency (26). We
eated With N-Acetylcysteine and With
roup
7)
Fenoldopam Group
(n  95) p Value
–1.90) 1.75 (1.62–2.01) 0.17
–1.86) 1.71 (1.48–2.03) 0.77
11 (11.5%) 0.45
16 40  14 0.33
20 70  21 0.27
26 63  21 0.32
3 141  3 0.30
8 141  4 0.44
0.6 4.5  0.6 0.76
0.6 4.5  0.6 0.75ts Tr
C G
n  9
(1.55
(1.40
(9%)
43 
66 
60 
41 
40 
.9 
.9 sed a dosing regimen that was double (1,200 mg orally
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August 18, 2004:762–5 Contrast Media and Acute Renal Failurewice daily) (19) that suggested by Tepel et al. (13) because
he antioxidant effect of NAC seems to be dose-dependent
27). With large volumes of contrast dye, the beneficial
ffect of the NAC may be evident only by using a dosing
egimen double that suggested by Tepel et al. (13).
enoldopam and CAN. Fenoldopam mesylate is the first
elective dopamine-1 receptor agonist approved for the
n-hospital treatment of patients with severe hypertension
14). A low dosage of fenoldopam that does not decrease
ystemic blood pressure produces dopamine-1 receptor-
ediated dose-related renal vasodilatation, diuresis, and
atriuresis (14). In dogs, fenoldopam protects against the
cute renal vasoconstriction that may be induced by contrast
gents (16). The protective effect of fenoldopam in patients
t risk of CAN might involve its ability to selectively
ncrease blood flow to the renal medulla. Although prelim-
nary studies suggest that the administration of fenoldopam
rotects against CAN (16–18), our finding confirms the
esults of the recent Controlled Multicenter Trial Evaluat-
ng Fenoldopam Mesylate for the Prevention of Contrast-
nduced Nephropathy (CONTRAST) trial (20), which
uggested that fenoldopam mesylate is ineffective in pre-
enting further renal function deterioration in patients with
hronic renal insufficiency receiving iodinated contrast.
ccording to these findings and considering also the high
ost of this drug, a strategy of hydration plus fenoldopam
esylate should not be used as a prophylactic measure to
revent CAN.
tudy limitations. Our study was not blinded. Fenoldopam
esylate increases renal blood flow in a dose-dependent
anner (14); hence, a dose 0.10 g/kg/min may be needed
o achieve an optimal prophylactic action against CAN. In-
reasing the dose, however, increases the risk of hypotension
ith resultant intrarenal vasoconstriction.
eprint requests and correspondence: Dr. Carlo Briguori, In-
erventional Cardiology, Clinica Mediterranea, Via Orazio, 2,
-80121, Naples, Italy. E-mail: briguori.carlo@hsr.it.
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